Divis Laboratories is currently trading at Rs. 1041.50, up by 31.75 points or 3.14% from its previous closing of Rs. 1009.75 on the BSE.
The scrip opened at Rs. 1025.00 and has touched a high and low of Rs. 1089.90 and Rs. 1025.00 respectively. So far 96,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1319.00 on 10-Nov-2016 and a 52 week low of Rs. 533.10 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 1089.90 and Rs. 992.55 respectively. The current market cap of the company is Rs. 27,652.00 crore.
The promoters holding in the company stood at 52.07%, while Institutions and Non-Institutions held 32.45% and 15.48% respectively.
The US Food and Drug Administration (USFDA) has completed evaluation of Divis Laboratories corrective actions in response to its Warning Letter dated April 13, 2017. The agency has closed-out the warning letter.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |